Evidence map›Paper›PMID 41112599›Full record

Trial reportWorld journal of psychiatry2025

Safety and efficacy of different initial doses of lurasidone in the schizophrenia treatment: A multi-center, randomized, open-label study.

Qi Liu, Min-Cai Qian, Zhi-Fen Liu, Fang Dong, Deng-Tang Liu, Ming-Li Li, Yu-Ping Ning, Xiao-Ping Wang, Tie-Bang Liu, Qi Wu and 2 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in World journal of psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Qi LiuDepartment of Psychological Counseling, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing 100191, China.
Min-Cai QianDepartment of Neurosis and Psychosomatic Diseases, The Third People's Hospital Affiliated to Huzhou University, Huzhou 313000, Zhejiang Province, China.
Zhi-Fen LiuDepartment of Psychiatry, The First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.
Fang DongBeijing Key Laboratory of Mental Disorders, The National Clinical Research Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing 100088, China.
Deng-Tang LiuDepartment of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
Ming-Li LiMental Health Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.
Yu-Ping NingDepartment of Neurology, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou 510370, Guangdong Province, China.
Xiao-Ping WangDepartment of Psychiatry, National Clinical Research Center for Mental Disorders, National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China.
Tie-Bang LiuDepartment of Psychiatry, Shenzhen Kangning Hospital, and Shenzhen Mental Health Center, Shenzhen 518118, Guangdong Province, China.
Qi WuSumitomo Pharma (China), Co., Ltd., Shanghai 200025, China.
Tao LiDepartment of Neurobiology, The Affiliated Mental Health Center and Hangzhou Seventh People's Hospital, Zhejiang University School of Medicine, Hangzhou 310063, Zhejiang Province, China.
Xin YuDepartment of Psychiatry, Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing 100191, China. yuxin@bjmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSchizophrenia, a complex group of mental disorders, is primarily managed with antipsychotic medications. The safety and efficacy of different initial doses of lurasidone for acute schizophrenia remain uncertain, particularly concerning discontinuation rates due to adverse events (AEs).

aimTo compare the safety of two initial doses of lurasidone for the treatment of acute schizophrenia in Chinese patients.

methodsThis 6-week, randomized, open-label, multicenter trial allocated participants to receive either 40 mg/day or 80 mg/day lurasidone initially, with dose adjustment allowed after a one-week fixed-dose period. Safety assessments included the primary endpoint of discontinuation due to AEs, as well as evaluations of AEs, weight changes, and laboratory parameters. Efficacy assessments included responder rates and changes in scores on the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression-Severity scale, and Calgary Depression Scale for Schizophrenia.

resultsAmong 197 participants, no significant difference was found in discontinuation rate due to AEs between groups (3.03%

conclusionInitial doses of 40 mg/day and 80 mg/day lurasidone are safe and effective for acute schizophrenia, with no significant increase in AEs-related discontinuation rate at the higher dose.

Indexed as

Discontinuation rateEfficacyLurasidoneSafetySchizophrenia

Identifiers

PMID41112599
PMCPMC12531967

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.